EL7.AI
StocksHigh ImpactUpdated•Originally published 10 March 2026•Updated 10 March 2026•
1 min read

BioNTech to Take Stake in Founders' New Venture, Pivots Focus to Oncology

Key Facts

1BioNTech cofounders Ugur Sahin and Oezlem Tuereci will leave the company by the end of 2026.
2The cofounders intend to form a new biotechnology startup focused on developing messenger RNA (mRNA).
3The announcement of their departure was made on Tuesday, March 10, 2026.

BioNTech SE has disclosed new details regarding the planned departure of its co-founders by 2026, outlining a strategic financial relationship with their new mRNA venture. Under the agreement, BioNTech will contribute specific rights and technologies to the startup in exchange for a minority equity stake. The deal also secures potential milestone payments and royalties for BioNTech, ensuring the company retains a financial interest in the founders' future scientific breakthroughs. Simultaneously, BioNTech announced plans to intensify its internal strategic focus on oncology, aiming to lead in the development of next-generation cancer treatments. Analysts suggest that these arrangements could mitigate investor concerns by providing a structured transition and a clear pivot for the company's core operations. While the leadership change remains significant, the equity stake and oncology focus offer a more defined roadmap for BioNTech’s post-2026 trajectory.